MedTrace Logo

IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation (TASMANIA)

NCT04832841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 753

Last updated 2024-03-06

No results posted yet for this study

Summary

The aim of this study is to assess humoral immune response in kidney transplant recipients after SARS-CoV-2 mRNA vaccine.

Conditions

  • Kidney Transplantation

Interventions

DIAGNOSTIC_TEST

anti-spike SARS-CoV-2 IgG

Immunochemiluminescent assay by DiaSorin S.p.A. Italy

Sponsors & Collaborators

  • Institute for Clinical and Experimental Medicine

    lead OTHER_GOV

Principal Investigators

  • Ondrej Viklicky, Prof. · Institute for Clinical and Experimental Medicine

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2021-09-30
Completion
2022-03-30

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04832841 on ClinicalTrials.gov